ReviewNature medicine2024
Advancing global antibiotic research, development and access.
Review in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Designing eligibility and evaluation criteria for antibacterial pull incentives: a comparative review of implemented and emerging initiatives.The Lancet regional health. Europe · 2026Article
- Bridging the divide between health economics and outcomes research and biomedical investment: reflections from a health economist working in venture capital.Journal of comparative effectiveness research · 2026Review
- Antibiotic Resistance and the Return to a Pre-Antibiotic Era: A Critical Narrative Review of a Global Catastrophe.Biomedicines · 2026Review
- A genome-wide CRISPRi screen identifies homologous recombination pathway as potential target for broad-spectrum antibiotic adjuvants.Journal of advanced research · 2026Article
- Expedited research and approval of medicines for drug-resistant bacterial infections in children.Bulletin of the World Health Organization · 2026Article
- Next-Generation Strategies to Encounter Antimicrobial Resistance (AMR): From Lariocidin to Gene Editing and Nanotechnology-Based Approaches.Molecules (Basel, Switzerland) · 2026Review
- Drug and country characteristics associated with global approval and launch of FDA-approved novel therapeutics.Health affairs scholar · 2026Article
- Dual Silencing of Aminoglycoside Biosynthesis for the Discovery of Novel Antimicrobials in Streptomyces.Microbial biotechnology · 2026Article
- Emergence, evolution, and global dissemination of antimicrobial resistance: A One Health review.Archives of microbiology · 2026Review
- Restoration of daptomycin sensitivity with adjunctive cefazolin is associated with C-terminal MprF mutations in MRSA bacteremia isolates.Antimicrobial agents and chemotherapy · 2026Article
- The Role of Combination Antibiotic Therapy in Combatting Drug-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- AntibioticDB: An Updated and Improved Open-Access Database for the Antibacterial Research and Development Community.ACS infectious diseases · 2026Article
- Halogenated Vitamin BACS omega · 2026Article
- Article
- Review
- Development of a nitric oxide-releasing cephalexin-based hybrid compound for enhanced antimicrobial efficacy and biofilm disruption.RSC medicinal chemistry · 2025Article
- Children's drug research and development incentives and market pricing optimization based on medical imaging.Scientific reports · 2025Article
- From Tears to Toxins: Mapping Antibiotic Passage Through the Eye-Liver Axis.Antibiotics (Basel, Switzerland) · 2025Review
- The Perspectives of Combining Antibiotics with Saponins-Herbal Excipients.Molecules (Basel, Switzerland) · 2025Review
- Bridging the fair share gap for antibacterial innovation: an observational analysis of antibacterial revenues in the G7 and EU27.EClinicalMedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pipeline of new antibiotics is insufficient to keep pace with the growing global burden of drug-resistant infections. Substantial economic challenges discourage private investment in antibiotic research and development (R&D), with a decline in the number of companies and researchers working in the field. Compounding these issues, many countries (from low income to high income) face a growing crisis of antibiotic shortages and inequitable access to existing and emerging treatments. This has led to an increasing role for public and philanthropic funding in supporting antibiotic R&D via the creation of nonprofit public-private partnerships, including Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) and the Global Antibiotic Research and Development Partnership (GARDP), industry support for the AMR Action Fund, and pilot schemes to evaluate and reimburse antibiotics in innovative ways. Now is the time to raise the urgency, ambition and commitments of the world's leaders to fully support the antibiotic R&D ecosystem, incentivizing all sectors to conduct public health-driven antibiotic R&D and make effective antibiotics accessible to all who need them.
Indexed as
Identifiers
39227444What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.